Improving pollen immunotherapy: minor allergens and panallergens
| Autor: | C Moreno-Aguilar |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_treatment Immunology Disease Cross Reactions medicine.disease_cause Cross-reactivity In vitro diagnostic Allergen Pollen otorhinolaryngologic diseases medicine Humans Immunology and Allergy Plant Proteins business.industry Rhinitis Allergic Seasonal Specific immunotherapy Cross reactions General Medicine Immunotherapy Allergens Antigens Plant Recombinant Proteins Desensitization Immunologic Spain business |
| Zdroj: | Allergologia et Immunopathologia. 36:26-30 |
| ISSN: | 0301-0546 |
| DOI: | 10.1157/13115668 |
| Popis: | Multiple sensitizations to pollens are common clinical situations in Spain, and alter the efficacy of allergen-specific immunotherapy. We now know that optimization of the diagnosis is required to define the best suited treatment for each patient. All pollen allergens belong to 29 families of proteins - the most abundant being the expansins, prophyllins and polcalcins. The ubiquitous nature of proteins such as the prophyllins and polcalcins defines them as panallergens, and explains the cross-reactivity that is erroneously interpreted by clinicians as constituting multi-sensitization. Other families of allergens, such as the calcium transporting proteins (LTPs) are more restricted, but are associated to severe types of allergic disease - this being particularly useful to decide upon the indication of immunotherapy. Although recombinant allergens can be produced for in vitro diagnostic purposes, current legislation only allows the use of natural proteins for immunotherapy. However, the same technology can be applied to the study of extracts for vaccines, and it seems that allergen quantification by the manufacturers is a no return trip which clinicians are obliged to follow. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|